Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement News, In Brief

Executive Summary

Some patient groups ask Congress not to consider Medicaid-style rebates for dual-eligibles and low-income subsidy recipients in Medicare Part D; 72% of office-based physicians are using electronic health records; disparities in Medicaid EHR adoption, based on allocation of incentive payments, mirror those found in Medicare EHR adoption.

You may also be interested in...



Mandated Part D Rebates Cannot Be Imposed Without Consequence To Beneficiaries, Holtz-Eakin Writes

In a Health Affairs Blog post, former CBO Director Douglas Holtz-Eakin takes issue with a recent article arguing that mandated Part D rebates would not lead to major Medicare premium increases or otherwise shift costs to Part D beneficiaries as well as employers.

Mandated Part D Rebates Would Not Lead To Higher Premiums, Cost Shifts, MedPAC Commissioner Argues

In an online Health Affairs article, MedPAC commissioner Jack Hoadley and co-author Richard Frank rebut arguments against mandatory rebates on Medicare Part D drugs.

Part D Mandatory Rebates Included In Speaker Boehner’s “Fiscal Cliff” Offer

House Speaker John Boehner made an offer to President Obama Dec. 3 to base a resolution to the looming fiscal cliff on a proposal by the president’s deficit commission headed by Erskine Bowles and Alan Simpson, a proposal that included a mandatory rebate on drugs used in Medicare Part D.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS054977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel